Linfomi non-Hodgkin, nuovi dati promettenti sul bispecifico glofitamab da solo o in combinazione

Glofitamab is a new drug in development, a highly promising bispecific antibody for the treatment of non-Hodgkin's lymphomas, particularly diffuse large B-cell lymphoma. At the recently concluded International Conference on Malignant Lymphoma (ICML) in Lugano, the results of several studies involving glofitamab, alone or in combination with other agents, were presented. We discuss this in this interview with Professor Carmelo Carlo Stella, Professor of Hematology at the Department of Biomedical Sciences at Humanitas University in Rozzano (MI).